Surgical Stapler Coating for Tissue Sealing at Staple Holes

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Surgical staplers often result in leaks due to staple forming holes, allowing fluids to seep through, which complicates wound healing and recovery.

Innovation Solution

Applying a coating on surgical staplers that contains a matrix metalloproteinase (MMP) inhibitor to control the interaction between the MMP inhibitor and the stapler's outer surface, preventing ECM degradation and minimizing tissue leakage.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If staples are used to close tissue openings, then tissue sealing is achieved, but fluid leakage occurs through staple forming holes

Engineering Contradiction:
Improvetissue sealingVSAvoidfluid leakage
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies a coating containing MMP inhibitors to the staple and adjacent tissue surfaces. MMP inhibitors normally prevent harmful ECM degradation, but when applied to the staple surface, they create a controlled interaction that promotes scar tissue formation at the staple insertion site. This converts the potential harm of staple hole leakage into a beneficial healing response, where the MMP inhibitor coating strengthens the insertion site and promotes tissue sealing.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent changes the chemical parameter of the staple surface by applying a coating containing MMP inhibitors. This coating modification alters the biological interaction at the staple-tissue interface, transforming the passive metal surface into an active healing promoter that reduces fluid leakage by strengthening the insertion site through controlled scar tissue formation.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If MMP inhibitor coating is applied to control interaction with outer surface, then ECM degradation is prevented, but coating application complexity increases

Engineering Contradiction:
ImproveECM protectionVSAvoidcoating application
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The MMP inhibitor coating is applied to the staple and adjacent surfaces before the stapling procedure. This preliminary application ensures that the protective and healing effects are already in place when the staples are deployed, eliminating the need for postoperative coating application and simplifying the overall procedure while maintaining reliable ECM protection.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The coating acts as an intermediary layer between the staple surface and the surrounding tissue. This intermediate coating containing MMP inhibitors mediates the interaction between the metal staple and biological tissues, preventing direct harmful contact while promoting controlled healing responses, thereby reducing the complexity of direct tissue-staple interaction management.

Inventive Principle:
Principle #24Intermediary (Mediator)

Data Source

PatentEP3964242B1Surgical stapler with end effector coating
Publication Date: 2026.02.18 CILAG GMBH INTERNATIONAL
  • EP3964242B1 patent drawingFigure 1
  • EP3964242B1 patent drawingFigure 2
  • EP3964242B1 patent drawingFigure 3

AI summary

Methods and devices are provided for promoting wound healing. In general, surgical staplers and stapler components are provided having a coating thereon that is configured to selectively control an interaction between at least one matrix metalloproteinase (MMP) inhibitor and an outer surface of the stapler or stapler component.